The API nanoparticles produced through Nanoform’s CESS technology and the Celanese VitalDose EVA copolymer delivery technology have the potential to enable enhanced sustained release
Nanoform Finland, an innovative nanoparticle medicine enabling company, and Celanese Corporation, a global specialty materials company, have provided an update on their collaboration to evaluate the synergies between their respective technologies in the field of nanoparticle-enabled drug delivery.
Together, the API nanoparticles produced through Nanoform’s CESS technology and the Celanese VitalDose EVA copolymer delivery technology for drug-eluting implants have the potential to enable enhanced sustained release properties by reducing the initial burst release of a drug, which is a persistent challenge in high drug load implants. The increased drug load enabled by the nanoformed particles also allows smaller implants with sustained release properties to be developed.
“We are delighted with these results,” said Christian Jones, CCO of Nanoform, “and are excited about the continued opportunity to explore not only the technical benefits that the combination of these two technologies offer but, more importantly, the benefits that they bring to patients.”
“We believe that the synergies in our technologies will enable more patient-centricity in drug development,” said Susan Rahe, VP at Celanese, “We look forward to our continued collaboration with Nanoform to further propel the innovation we provide to the industry."